Rituximab

Generic Name
Rituximab
Brand Names
MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
Drug Type
Biotech
Chemical Formula
-
CAS Number
174722-31-7
Unique Ingredient Identifier
4F4X42SYQ6
Background

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication

Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions
Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
Associated Therapies
-
Clinical Trials
Related News

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT06738368
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma

First Posted Date
2024-12-12
Last Posted Date
2024-12-12
Lead Sponsor
University of Miami
Target Recruit Count
20
Registration Number
NCT06730542
Locations
🇺🇸

University of Miami, Miami, Florida, United States

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1046
Registration Number
NCT06717347

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

First Posted Date
2024-11-26
Last Posted Date
2024-11-26
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
20
Registration Number
NCT06704555
Locations
🇨🇳

Tianjin Cancer Hospital, Tianjin, Tianjin, China

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

First Posted Date
2024-11-22
Last Posted Date
2024-11-22
Lead Sponsor
Fei Li
Target Recruit Count
90
Registration Number
NCT06700798
Locations
🇨🇳

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

First Posted Date
2024-11-12
Last Posted Date
2024-11-26
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
182
Registration Number
NCT06682169
Locations
🇨🇳

The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

First Posted Date
2024-11-06
Last Posted Date
2024-11-06
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
18
Registration Number
NCT06676631

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

First Posted Date
2024-10-24
Last Posted Date
2024-11-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
86
Registration Number
NCT06655896
Locations
🇺🇸

University Of Iowa, Iowa City, Iowa, United States

🇸🇬

Novartis Investigative Site, Singapore, Singapore

Zanubrutinib Plus Rituximab As Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
42
Registration Number
NCT06647732
Locations
🇨🇳

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2024-10-16
Last Posted Date
2024-10-23
Lead Sponsor
Jennifer R. Brown, MD, PhD
Target Recruit Count
64
Registration Number
NCT06644183
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy